Scientific Advisory Board
The scientific work of the NCT is overseen by a Scientific Advisory Board consisting of external world-class experts and two patient representatives chaired by Raymond DuBois (Medical University of South Carolina). In addition, two members of the NCT SAB serve in a dual role on the German Cancer Consortium (DKTK) SAB, thereby ensuring alignment of activities. The composition of the Scientific Advisory Board is intended to cover the entire spectrum of clinical translational cancer research. The experts of the NCT Scientific Advisory Board are proposed by the Managing Directorates, while the National Patient Council is entitled to nominate the patient representatives. The experts of the Scientific Advisory Board are appointed by the Steering Committee for five years, with the option for one reappointment. The decision on the appointment requires a majority of three-quarters of members present.
The Scientific Advisory Board advises the Foundation Council, the Steering Committee and the General Committee of Parental Institutions on scientific matters and regularly comments on the scientific performance and draft research and development programs of the NCT sites. The Scientific Advisory Board meets at least once a year, supplemented by additional meetings between the Steering Committee spokespersons and the chair of the SAB, as well as between the chairs of the SABs of NCT and DKTK, to ensure alignment and foster synergy across programs.
| DuBois, Ray (Chair) | Medical University of South Carolina, USA |
| Baeuerle, Patrick | Cullinan Therapeutics Cambridge, USA |
| Bian, Jiang | University of Florida, USA |
| Brindle, Kevin | Cancer Research UK Cambridge Institute, UK |
| Bristow, Robert | Manchester Cancer Research Centre, UK |
| Caligaris-Cappio, Federico | AIRC Scientific Director, Italy |
| Grau, Cai | Aarhus University Hospital, Denmark |
| Kirkby, Karen | Professor emerita, University of Manchester, UK |
| Le Beau, Michelle | Director emerita, University of Chicago Comprehensive Cancer Center, USA |
| Lecointe-Artzner, Estelle | Patient advocate, Info Sarcomes, France |
| Mardis, Elaine | Nationwide Children’s Hospital, Columbus, USA |
| Maskens, Deborah | Patient advocate, Kidney Cancer Canada |
| Melief, Cornelis | ISA Pharmaceuticals, The Netherlands |
| Melillo, Giovanni | AstraZeneca, USA |
| Mousavi, Parvin | Queen’s University, Canada |
| Naredi, Peter | University of Gothenburg and Sahlgrenska University Hospital, Sweden |
| Serrano, César | Vall d’Hebron Institute of Oncology, Spain |
| Tabernero, Josep | Vall d’Hebron Institute of Oncology, Spain |
| Vester-Blokland, Estelle | Advisor to FatiAbGen, Switzerland |
| Vyas, Paresh | University of Oxford, UK |
| Ware, John | Tufts University School of Medicine, USA |
| Zitvogel, Laurence | Gustave Roussy Cancer Center, France |